Smile Insights+
introduces itself

The Kaske Group Knowledge Hub

Here you will find the combined expertise of Smile.BI GmbH, covering all aspects of e-commerce and the pharmaceutical industry. We draw on the Kaske Group’s wealth of knowledge and experience, which has grown since 1997.

We have always made some of our knowledge freely available. Our studies, case studies, white papers, webinars and our Digital Performance Index (Dx) are just a few examples of this. Our studies have always been available in a public, abridged version and in a full version with all insights. These full versions were previously only available internally and as part of the collaboration.

With Smile Insights+, everyone can now gain access to these exclusive insights. The previously public content will continue to be freely available. All you have to do is register once free of charge and confirm your e-mail address. After that you will have access to the current content and our archive back to 2020.

More content, deeper insights and industry news

  • You only need to register once and have access to all free content
  • Smile Insights+ is the central knowledge portal within the Kaske Group for manufacturers in the pharmaceutical market
  • We have much more content in the pipeline than ever before.

Members have access to:

  • 6 new studies (public version) incl. Comment function.
    Exchange ideas with other users of the platform and the Smile.BI team.
  • Access to our studies from 2019 (public versions)
  • 7 new live webinars
  • 12 new editions of the Digital Performance Index (Dx)
  • 12 times news from the Kaske Group by e-mail
  • Access all languages with just one login

What’s new on Smile Insights+

Cosa significano i simboli dietro i titoli?

(✚) = Contenuto per i membri base e i membri plus

✚ = Esclusivamente per i membri plus

senza ✚ = Contenuti disponibili per tutti su Smile Insights+.

I contenuti per i membri plus coprono attualmente soprattutto il mercato tedesco.
I contenuti sono in tedesco e in parte in inglese.